Harrow Health, Inc.

Harrow Health, Inc. Q3 2026 Earnings Recap

HROW Q3 2026 Published November 15, 2026

Get alerts when HROW reports next quarter

Set up alerts — free

Harrow’s shares rose 10.5% after revenue reached a record $99.3 million, up 39% year over year, and the company reaffirmed full-year revenue guidance. The outlook calls for a substantial Q4 step-up, while management flagged gross margins as lower than expected.

Earnings Per Share Beat
$0.25 vs $0.19 est.
+28.6% surprise
Revenue Beat
99297000 vs 98595330 est.
+0.7% surprise

Market Reaction

Post-Earnings +10.52%

See HROW alongside your other holdings

Add to your portfolio — free

Key Takeaways

  • Branded revenue was $83.5 million, up about 62% year over year and roughly 84% of total revenue; compounded revenue was $15.8 million.
  • VEVYE generated $39.7 million, IHEEZO $25.3 million, and TRIESENCE $10.7 million. VEVYE revenue rose 35% sequentially.
  • GAAP gross margin was 75%, up from 71% in Q2 and consistent with a year ago, but below management’s expectations due largely to compounded-product margins and mix.
  • Adjusted EBITDA was $21.2 million versus a $1.2 million loss in Q2; GAAP net income was $9.8 million, including a one-time $5 million litigation settlement gain in other income.
  • Full-year revenue guidance was reaffirmed at $350 million–$365 million, implying Q4 revenue of roughly $136 million–$151 million, or 37%–52% sequential growth.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit HROW on AllInvestView.

Get the Full Picture on HROW

Track Harrow Health, Inc. in your portfolio with real-time analytics, dividend tracking, and more.

View HROW Analysis